Meta-analysis of the efficacies of amiodarone and nifekalant in shock-resistant ventricular fibrillation and pulseless ventricular tachycardia

Shiho Sato, Yoshito Zamami, Toru Imai, Satoshi Tanaka, Toshihiro Koyama, Takahiro Niimura, Masayuki Chuma, Tadashi Koga, Kenshi Takechi, Yasuko Kurata, Yutaka Kondo, Yuki Izawa-Ishizawa, Toshiaki Sendo, Hironori Nakura, Keisuke Ishizawa

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Amiodarone (AMD) and nifekalant (NIF) are used in the treatment of ventricular fibrillation or tachycardia; however, only few studies have been conducted on their efficacies. Therefore, a meta-analysis was conducted. Relevant sources were identified from PubMed, Cochrane Central Register of Controlled Trials, and Igaku Chuo Zasshi. The outcomes were short-term and long-term survival in patients with shock-resistant ventricular fibrillation/pulseless ventricular tachycardia. Thirty-three studies were analysed. The results showed that, compared to the control treatment, AMD did not improve short-term survival (odds ratio (OR): 1.25, 95% confidence interval (CI): 0.91-1.71) or long-term survival (OR: 1.00, 95% CI: 0.63-1.57). However, compared to the control treatment, NIF significantly improved short-term survival (OR: 3.23, 95% CI: 2.21-4.72) and long-term survival (OR: 1.88, 95% CI: 1.36-2.59). No significant difference was observed in short-term survival (OR: 0.85, 95% CI: 0.63-1.15) or long-term survival (OR: 1.25, 95% CI: 0.67-2.31) between AMD-A nd NIF-treated patients. The results suggest that NIF is beneficial for short-term and long-term survival in shock-resistant ventricular fibrillation/pulseless ventricular tachycardia; however, the efficacy of AMD in either outcome is not clear.

Original languageEnglish
Article number12683
JournalScientific Reports
Volume7
Issue number1
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Amiodarone
Ventricular Fibrillation
Ventricular Tachycardia
Meta-Analysis
Shock
Survival
Odds Ratio
Confidence Intervals
nifekalant
PubMed
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

Meta-analysis of the efficacies of amiodarone and nifekalant in shock-resistant ventricular fibrillation and pulseless ventricular tachycardia. / Sato, Shiho; Zamami, Yoshito; Imai, Toru; Tanaka, Satoshi; Koyama, Toshihiro; Niimura, Takahiro; Chuma, Masayuki; Koga, Tadashi; Takechi, Kenshi; Kurata, Yasuko; Kondo, Yutaka; Izawa-Ishizawa, Yuki; Sendo, Toshiaki; Nakura, Hironori; Ishizawa, Keisuke.

In: Scientific Reports, Vol. 7, No. 1, 12683, 01.12.2017.

Research output: Contribution to journalArticle

Sato, S, Zamami, Y, Imai, T, Tanaka, S, Koyama, T, Niimura, T, Chuma, M, Koga, T, Takechi, K, Kurata, Y, Kondo, Y, Izawa-Ishizawa, Y, Sendo, T, Nakura, H & Ishizawa, K 2017, 'Meta-analysis of the efficacies of amiodarone and nifekalant in shock-resistant ventricular fibrillation and pulseless ventricular tachycardia', Scientific Reports, vol. 7, no. 1, 12683. https://doi.org/10.1038/s41598-017-13073-0
Sato, Shiho ; Zamami, Yoshito ; Imai, Toru ; Tanaka, Satoshi ; Koyama, Toshihiro ; Niimura, Takahiro ; Chuma, Masayuki ; Koga, Tadashi ; Takechi, Kenshi ; Kurata, Yasuko ; Kondo, Yutaka ; Izawa-Ishizawa, Yuki ; Sendo, Toshiaki ; Nakura, Hironori ; Ishizawa, Keisuke. / Meta-analysis of the efficacies of amiodarone and nifekalant in shock-resistant ventricular fibrillation and pulseless ventricular tachycardia. In: Scientific Reports. 2017 ; Vol. 7, No. 1.
@article{c64701bd5c6e481bad0f0024093642f8,
title = "Meta-analysis of the efficacies of amiodarone and nifekalant in shock-resistant ventricular fibrillation and pulseless ventricular tachycardia",
abstract = "Amiodarone (AMD) and nifekalant (NIF) are used in the treatment of ventricular fibrillation or tachycardia; however, only few studies have been conducted on their efficacies. Therefore, a meta-analysis was conducted. Relevant sources were identified from PubMed, Cochrane Central Register of Controlled Trials, and Igaku Chuo Zasshi. The outcomes were short-term and long-term survival in patients with shock-resistant ventricular fibrillation/pulseless ventricular tachycardia. Thirty-three studies were analysed. The results showed that, compared to the control treatment, AMD did not improve short-term survival (odds ratio (OR): 1.25, 95{\%} confidence interval (CI): 0.91-1.71) or long-term survival (OR: 1.00, 95{\%} CI: 0.63-1.57). However, compared to the control treatment, NIF significantly improved short-term survival (OR: 3.23, 95{\%} CI: 2.21-4.72) and long-term survival (OR: 1.88, 95{\%} CI: 1.36-2.59). No significant difference was observed in short-term survival (OR: 0.85, 95{\%} CI: 0.63-1.15) or long-term survival (OR: 1.25, 95{\%} CI: 0.67-2.31) between AMD-A nd NIF-treated patients. The results suggest that NIF is beneficial for short-term and long-term survival in shock-resistant ventricular fibrillation/pulseless ventricular tachycardia; however, the efficacy of AMD in either outcome is not clear.",
author = "Shiho Sato and Yoshito Zamami and Toru Imai and Satoshi Tanaka and Toshihiro Koyama and Takahiro Niimura and Masayuki Chuma and Tadashi Koga and Kenshi Takechi and Yasuko Kurata and Yutaka Kondo and Yuki Izawa-Ishizawa and Toshiaki Sendo and Hironori Nakura and Keisuke Ishizawa",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41598-017-13073-0",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Meta-analysis of the efficacies of amiodarone and nifekalant in shock-resistant ventricular fibrillation and pulseless ventricular tachycardia

AU - Sato, Shiho

AU - Zamami, Yoshito

AU - Imai, Toru

AU - Tanaka, Satoshi

AU - Koyama, Toshihiro

AU - Niimura, Takahiro

AU - Chuma, Masayuki

AU - Koga, Tadashi

AU - Takechi, Kenshi

AU - Kurata, Yasuko

AU - Kondo, Yutaka

AU - Izawa-Ishizawa, Yuki

AU - Sendo, Toshiaki

AU - Nakura, Hironori

AU - Ishizawa, Keisuke

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Amiodarone (AMD) and nifekalant (NIF) are used in the treatment of ventricular fibrillation or tachycardia; however, only few studies have been conducted on their efficacies. Therefore, a meta-analysis was conducted. Relevant sources were identified from PubMed, Cochrane Central Register of Controlled Trials, and Igaku Chuo Zasshi. The outcomes were short-term and long-term survival in patients with shock-resistant ventricular fibrillation/pulseless ventricular tachycardia. Thirty-three studies were analysed. The results showed that, compared to the control treatment, AMD did not improve short-term survival (odds ratio (OR): 1.25, 95% confidence interval (CI): 0.91-1.71) or long-term survival (OR: 1.00, 95% CI: 0.63-1.57). However, compared to the control treatment, NIF significantly improved short-term survival (OR: 3.23, 95% CI: 2.21-4.72) and long-term survival (OR: 1.88, 95% CI: 1.36-2.59). No significant difference was observed in short-term survival (OR: 0.85, 95% CI: 0.63-1.15) or long-term survival (OR: 1.25, 95% CI: 0.67-2.31) between AMD-A nd NIF-treated patients. The results suggest that NIF is beneficial for short-term and long-term survival in shock-resistant ventricular fibrillation/pulseless ventricular tachycardia; however, the efficacy of AMD in either outcome is not clear.

AB - Amiodarone (AMD) and nifekalant (NIF) are used in the treatment of ventricular fibrillation or tachycardia; however, only few studies have been conducted on their efficacies. Therefore, a meta-analysis was conducted. Relevant sources were identified from PubMed, Cochrane Central Register of Controlled Trials, and Igaku Chuo Zasshi. The outcomes were short-term and long-term survival in patients with shock-resistant ventricular fibrillation/pulseless ventricular tachycardia. Thirty-three studies were analysed. The results showed that, compared to the control treatment, AMD did not improve short-term survival (odds ratio (OR): 1.25, 95% confidence interval (CI): 0.91-1.71) or long-term survival (OR: 1.00, 95% CI: 0.63-1.57). However, compared to the control treatment, NIF significantly improved short-term survival (OR: 3.23, 95% CI: 2.21-4.72) and long-term survival (OR: 1.88, 95% CI: 1.36-2.59). No significant difference was observed in short-term survival (OR: 0.85, 95% CI: 0.63-1.15) or long-term survival (OR: 1.25, 95% CI: 0.67-2.31) between AMD-A nd NIF-treated patients. The results suggest that NIF is beneficial for short-term and long-term survival in shock-resistant ventricular fibrillation/pulseless ventricular tachycardia; however, the efficacy of AMD in either outcome is not clear.

UR - http://www.scopus.com/inward/record.url?scp=85030715238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030715238&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-13073-0

DO - 10.1038/s41598-017-13073-0

M3 - Article

C2 - 28978927

AN - SCOPUS:85030715238

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 12683

ER -